Core Insights - Biomerica has received three patent notices of allowance in Europe for its inFoods® Technology, targeting significant markets for GERD, Crohn's Disease, and Ulcerative Colitis, which are valued at over $4 billion, $2.5 billion, and $1.9 billion respectively [1][4][5] Market Potential - The GERD treatment market in Europe exceeds $4 billion annually, with a prevalence of symptoms affecting 8.8% to 25.9% of Europeans weekly [3] - The market for Crohn's Disease treatments in Europe is estimated at $2.5 billion annually, indicating a need for innovative treatment approaches [4] - The European market for Ulcerative Colitis is projected to grow from $1.5 billion in 2023 to over $1.9 billion by 2028 [4] Company Developments - The recent patent allowances mark a significant milestone for Biomerica in enhancing patient care through personalized medical solutions [5] - Biomerica's inFoods® Technology is a diagnostic-guided platform that identifies specific foods triggering symptoms in patients, allowing for personalized dietary plans [6][7] - The company is currently marketing inFoods® for IBS, which is already protected by 15 patents globally, and aims to expand its offerings to include treatments for GERD, Crohn's Disease, and Ulcerative Colitis [5][8] Product Benefits - inFoods® offers a non-drug, dietary-based solution for GERD, presenting a safer alternative to proton pump inhibitors, which are linked to serious health risks [7] - For Crohn's Disease and Ulcerative Colitis, inFoods® supports tailored dietary interventions that may reduce symptom severity and healthcare costs [7]

Core Insights - Biomerica, Inc. has enhanced its inFoods® IBS platform, allowing US consumers to order the inFoods® IBS test online and collect samples at home with physician oversight [1][2][6] - The inFoods® IBS test offers a personalized, non-invasive solution for managing Irritable Bowel Syndrome (IBS) symptoms by identifying specific food triggers [2][3] - A recent clinical study showed that the inFoods® IBS test significantly improved key IBS symptoms, such as Abdominal Pain Intensity (API) and bloating, without the side effects associated with traditional drug therapies [4][8] Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products for medical conditions, particularly gastrointestinal and inflammatory diseases [7] - The company aims to enhance health and well-being while reducing healthcare costs through its innovative products [7] Industry Context - IBS affects approximately 1 in 20 Americans, leading to an estimated $10 billion in annual direct medical costs, highlighting the economic burden of the condition [5] - The complexity of IBS often leaves patients struggling to find effective treatments, creating a significant market opportunity for personalized solutions like the inFoods® IBS test [5][6]

Core Insights - Biomerica reported a 6% increase in total revenue for the first quarter of fiscal 2025, reaching $1.8 million compared to $1.7 million in the same period last year, driven by higher demand and new contracts [3][7] - The company has implemented cost-saving measures expected to reduce annual expenses by 16% to 23%, translating to savings of $1.0 million to $1.4 million [4] - Biomerica's at-home PSA screening test has received approval from the Saudi Food and Drug Authority, enhancing accessibility for early prostate cancer detection [2] Financial Performance - Revenue for the first quarter of fiscal 2025 was $1.8 million, up from $1.7 million in the prior year [3][7] - Gross margin decreased to 16% from 24% year-over-year, impacted by one-time reduction-in-force costs [4][7] - Operating expenses rose slightly to $1.7 million from $1.6 million, primarily due to severance costs and new sales force expenses [5][7] - Operating loss increased to $1.4 million from $1.2 million, while net loss rose to $1.3 million from $1.1 million, largely due to RIF-related expenses [6][7] Product Developments - The inFoods® IBS pilot program with a group of 1,100 physicians has been completed, with potential for a systemwide launch based on positive results [2] - Biomerica is exploring distribution partnerships for inFoods® IBS to expand its market reach [2] - The company is in discussions with major clinical laboratories for its hp+detect™ product, which offers cost-effective and superior detection of Helicobacter pylori [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbols Name of each exchange on which registered Common Stock, par value $0.08 BMRA Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37 ...

- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country. This at-home test is designed to empower men with the ability to detect early w ...

Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger Growth Significant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $1.0 to $1.4 Million in the Coming Year inFoods® IBS Pilot with Large 1,100 Physician Group Progressing Ahead of Schedule IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company ac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbols Name of each exchange on which registered Common Stock, par value $0.08 BMRA Nasdaq Capital Market FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Transition Period From ______ To ______ Commission File Number: 001 ...

Impact of IBS and Economic Burden Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica prima ...

inFoods® IBS test is the first of its kind to identify specific foods that can trigger an Irritable Bowel Syndrome (IBS) symptoms "Our goal is to deliver cost-effective, non-pharmaceutical solutions that manage IBS by pinpointing and eliminating specific dietary triggers," said Zack Irani, CEO of Biomerica. "This innovation is an important step to opening access to IBS patients and their healthcare providers." inFoods® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick ...

With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inFoods IBS offers a groundbreaking method to identify foods that can trigger IBS symptoms, revolutionizing how IBS symptoms are managed. inFoods IBS is backed by extensive clinical research that has demonstrated remarkable ef ...